Novartis to buy Spinifex for $200 mln

Novartis International AG has agreed to buy Spinifex Pharmaceuticals Inc. for an upfront cash consideration of $200 million plus undisclosed clinical development and regulatory milestone payments. based in Stamford, Connecticut and Melbourne, Australia, Spinifex develops drugs for the treatment of chronic pain. Deutsche Bank advised Spinifex. Spinifex's investors include Novo A/S, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest (University of Queensland, Australia).

North AmericaUSBriefs